SCHEMBL17490396

SCHEMBL17490396

CCC(O)(C1CCCC1)C1CCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 5/20 0.36
CHRM1 P11229 5/20 0.36
CYP2D6 P10635 4/20 0.36
KCNH2 Q12809 4/20 0.36
CHRM3 P20309 3/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
TSHR P16473 2/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
HRH1 P35367 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21810986 0.97 CHRM2 (0.39) CHRM2CHRM1CYP2D6KCNH2CHRM3
SCHEMBL28508058 0.95 CHRM2 (0.38) CHRM2CHRM1CYP2D6KCNH2CHRM3
SCHEMBL10942478 0.79 CYP1A2 (0.41) CHRM2CHRM1CYP2D6KCNH2CHRM3
SCHEMBL14463009 0.78 CYP1A2 (0.33) CHRM2CHRM1CYP2D6KCNH2CYP1A2
Methane SCHEMBL28302061 0.77 CYP1A2 (0.39) CHRM2CHRM1CYP2D6KCNH2CHRM3
Alcohol SCHEMBL28368399 0.77 CYP1A2 (0.34) CHRM2CHRM1CYP2D6KCNH2CYP1A2
SCHEMBL2580716 0.76 CYP1A2 (0.37) CHRM2CHRM1CYP2D6KCNH2CYP1A2
SCHEMBL10234483 0.76 CYP1A2 (0.37) CHRM2CHRM1CYP2D6KCNH2CYP1A2
SCHEMBL14048439 0.76 CYP1A2 (0.32) CHRM2CHRM1CYP2D6KCNH2CYP1A2
SCHEMBL10876431 0.74 CYP1A2 (0.36) CHRM2CHRM1CYP2D6KCNH2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160031868-A1 BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. 2016-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031868-A1 BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 CHRM2 2750/4885CHRM1 1871/4885CYP2D6 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.